$34M 2027 revenueStrategic acquisitionHealthcare & Life SciencesCompleted
Axogen closes BioCircuit Technologies deal for NerveTape
Axogen completed its acquisition of BioCircuit Technologies, maker of the first FDA-cleared sutureless nerve repair device, expected to add about $34 million to 2027 revenue.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Following healthcare M&A?
The next big healthcare deal will be in our email the morning after it's announced, with the rest of the day's biggest deals. Free, with no paywalled links.
See what you get →